Prevalence of liver tumours in HIV-1 tat-transgenic mice treated with urethane

European Journal of Cancer

Volumn 40, Issue 2, 2004, Pages 275-283

  Altavilla, G ^a   Caputo, A ^b   Trabanelli, C ^b   Brocca Cofano, E ^b   Sabbioni, S ^b   Menegatti, M A ^b   Barbanti Brodano, G ^b   Corallini, A ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

HIV 1 tat; Liver and lung tumours; Oncogenesis; Urethane

Indexed keywords

CARCINOGEN; COMPLEMENTARY DNA; TRANSACTIVATOR PROTEIN; URETHAN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEUPLOIDY; ANGIOGENESIS; ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL DIVISION; CELL PROLIFERATION; CHEMISTRY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; IATROGENIC DISEASE; IMMUNOHISTOCHEMISTRY; INCIDENCE; LIVER; LIVER CARCINOMA; LIVER TUMOR; LUNG TUMOR; LYMPHOMA; MALE; METHODOLOGY; MOLECULAR CLONING; MOUSE; MUTAGENESIS; NONHUMAN; NUCLEIC ACID HYBRIDIZATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 0347915529     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.08.025     Document Type: Article

References (51)

1. Beral V., Jaffe H., Weiss R. Cancer, HIV and AIDS. Cancer Surv. 10:1991;1-3.
2. Biggar R.J. Cancer in the acquired immunodeficiency syndrome: an epidemiological assessment. Semin. Oncol. 17:1990;251-260.
3. Cremer K.J., Spring S.B., Gruber J. Role of human immunodeficiency virus type 1 and other viruses in malignancies associated with acquired immunodeficiency syndrome. J. Natl. Cancer Inst. 82:1990;1016-1025.
4. Ensoli B., Buonaguro L., Barillari G.et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67:1993;277-287.
5. Chang H.C., Samaniego F., Nair B.C., Buonaguro L., Ensoli B. HIV-1 tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS. 11:1997;1421-1431.
6. Frankel A.D., Pabo C.O. Cellular uptake of the Tat protein from human immunodeficiency virus. Cell. 55:1988;1189-1193.
7. Helland D.E., Welles J.L., Caputo A., Haseltine W.A. Transcellular transactivation by the human immunodeficiency virus type 1 Tat protein. J. Virol. 65:1991;4547-4549.
8. Ensoli B., Barillari G., Salahuddin Z.S., Gallo R.C., Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 345:1990;84-86.
9. Ensoli B., Gendelman R., Markham P.et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature. 371:1994;674-680.
10. Albini A., Barillari G., Benelli R., Gallo R.C., Ensoli B. Tat, the human immunodeficiency virus type 1 regulatory protein, has angiogenic properties. Proc. Natl. Acad. Sci. U.S.A. 92:1995;4838-4842.
11. Zauli G., Gibellini D., Milani D.et al. Human immunodeficiency virus type 1 Tat protein protects lymphoid, epithelial, and neuronal cell lines from death by apoptosiss. Cancer Res. 53:1993;4481-4485.
12. Campioni D., Corallini A., Zauli G., Possati L., Altavilla G., Barbanti-Brodano G. HIV type 1 extracellular Tat protein stimulates growth and protects cells of BK virus/tat transgenic mice from apoptosis. AIDS Res. Hum. Retrov. 11:1995;1039-1048.
13. Caputo A., Betti M., Boarini C., Mantovani I., Corallini A., Barbanti-Brodano G. Multiple functions of human immunodeficiency virus type 1 Tat protein in the pathogenesis of AIDS. Pandalai S.G. Recent Research Developments in Virology, Vol. 1. 1999;753-771 Transworld Research Network, Trivandrum.
14. Vogel J., Hinrichs S.H., Reynolds R.K., Luciw P.A., Jay G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature. 355:1988;606-611.
15. Corallini A., Altavilla G., Pozzi L.et al. Systemic expression of HIV-1 tat gene in transgenic mice induces endothelial proliferation and tumors of different histotypes. Cancer Res. 53:1993;5569-5575.
16. Altavilla G., Trabanelli C., Merlin M.et al. Morphological, histological, immunohistological, and ultrastructural characterization of tumors, dysplastic and non-neoplastic lesions arising in BK virus/tat transgenic mice. Am. J. Pathol. 154:1999;1231-1244.
17. Kim C.M., Vogel J., Jay G., Rhim J.S. The HIV tat gene transforms human keratinocytes. Oncogene. 7:1992;1525-1529.
18. Dragani T.A., Sozzi G., Della Porta G. Spontaneous and urethane-induced tumor incidence in B6C3F1 versus B6CF1 mice. Tumori. 70:1984;485-490.
19. Re F., Manenti G., Borello M.G.et al. Multiple molecular alterations in mouse lung tumors. Mol. Carcinogenesis. 5:1992;155-160.
20. Dragani T.A., Manenti G., Colombo B.M.et al. Incidence of mutations at codon 61 of the Ha-ras gene in liver tumors of mice genetically susceptible and resistant to hepatocarcinogenesis. Oncogene. 6:1991;333-338.
21. Dragani T.A., Manenti G., Della Porta G. Quantitative analysis of genetic susceptibility to liver and lung carcinogenesis in mice. Cancer Res. 51:1991;6299-6303.
22. Gariboldi M., Manenti G., Canzian F.et al. Chromosome mapping of murine susceptibility loci to liver carcinogenesis. Cancer Res. 53:1993;209-211.
23. Gariboldi M., Manenti G., Canzian F.et al. A major susceptibility locus to murine lung carcinogenesis maps on chromosome 6. Nature Genet. 3:1993;132-136.
24. Balansky R., Blagoeva P., Mircheva Z. Clastogenic activity of urethane in mice. Mutat. Res. 281:1992;99-103.
25. Koen H., Pugh T., Goldfarb S. Hepatocarcinogenesis in the mouse. Combined morphologic-stereologic studies. Am. J. Pathol. 112:1983;89-100.
26. Becker F.F. Morphological classification of mouse liver tumors based on biological characteristics. Cancer Res. 42:1982;3918-3923.
27. Solt D.B., Medline A., Farber E. Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis. Am. J. Pathol. 88:1977;595-618.
28. Stewart H.L., Dunn T.B., Snell K.C., Deringer M.K. Tumors of the respiratory tract. World Health Organization Pathology of Tumors in Laboratory Animals. Turusov V.S. Tumors of the Mouse, Vol. 2. 1979;251-288 IARC, Lyon.
29. Sambrook J., Russell D.W. Molecular Cloning: A Laboratory Manual, Vol. 2. 3rd edn. 2001;Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
30. 32P-postlabelling in liver and lung DNA of mice treated with ethyl carbamate (urethane) or its metabolites. Carcinogenesis. 17:1996;1711-1718.
31. Barbin A. Formation of DNA etheno adducts in rodents and humans and their role in carcinogenesis. Acta Biochim. Pol. 45:1998;145-161.
32. Barbin A. Etheno-adduct-forming chemicals. from mutagenicity testing to tumor mutation spectra Mutat. Res. 462:2000;55-69.
33. Ohmori H., Abe T., Hirano H.et al. Comparison of Ki-ras gene mutation among simultaneously occuring multiple urethane-induced lung tumors in individual mice. Carcinogenesis. 13:1992;851-855.
34. Kawano R., Nishisaka T., Takeshima Y., Yonehara S., Inai K. Role of point mutation of the K-ras gene in tumorigenesis of B6C3F1 mouse lung lesions induced by urethane. Japan J. Cancer Res. 86:1995;802-810.
35. Karasaki H., Obata M., Ogawa K., Lee G.H. Roles of the Pas1 and Par2 genes in determination of the unique, intermedial susceptibility of BALB/cByJ mice to urethane-induction of lung carcinogenesis. differential effects on tumor multiplicity, size and Kras2 mutations Oncogene. 15:1997;1833-1840.
36. Horio Y., Chen A., Rice P., Roth J.A., Malkinson A.M., Schrump D.S. Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Mol. Carcinogenesis. 17:1996;217-223.
37. Hennings H., Robinson V.A., Yuspa S.H., Welty D.J., Greenhalgh D.G. Activation of the rasHa gene in urethane-initiated papillomas induced by protocols with high and low frequencies of malignant conversation. Cancer Commun. 3:1991;277-281.
38. Watson M.A., Devereux T.R., Malarkey D.E., Anderson M.W., Maronpot R.R. H-ras oncogene mutation spectra in B6C3F1 and C57BL/6 mouse liver tumors provide evidence for TCDD promotion of spontaneous and vinyl carbamate-initiated liver cells. Carcinogenesis. 16:1995;1705-1710.
39. Ohno J., Horio Y., Sekido Y.et al. Telomerase activation and p53 mutations in urethane-induced A/J mouse lung tumor development. Carcinogenesis. 22:2001;751-756.
40. Westendorp M.O., Shatrov V.A., Schulze-Osthoff K.et al. HIV-1 Tat potentiates TNF-induced NF-κB activation and cytotoxicity by altering the cellular redox state. EMBO J. 14:1995;546-554.
41. Altavilla G., Caputo A., Lanfredi M., Piola C., Barbanti-Brodano G., Corallini A. Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene. Am. J. Pathol. 157:2000;1081-1089.
42. Scala G., Ruocco M.R., Ambrosino C.et al. The expression of the interleukin 6 gene induced by the human immunodeficiency virus type 1 Tat protein. J. Exp. Med. 179:1994;961-971.
43. Westendorp M.O., Li-Weber M., Frank R.W., Krammer P.H. Human immunodeficiency virus type 1 upregulates interleukin 2 secretion in activated T cells. J. Virol. 68:1994;4177-4185.
44. De Marchi F., d'Adda di Fagagna F., Falaschi A., Giacca M. Activation of transcription factor NF-κB by the Tat protein of human immunodeficiency virus type-1. J. Virol. 70:1996;4427-4437.
45. Li R., Yerganian G., Duesberg P.et al. Aneuploidy correlated 100% with chemical transformation of chinese hamster cells. Proc. Natl. Acad. Sci. U.S.A. 94:1997;14506-14511.
46. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature. 396:1998;643-649.
47. Turusov V.S., Takayama S. Tumors of the liver. World Health Organization Pathology of Tumors in Laboratory Animals. Turusov V.S. Tumors of the Mouse, Vol. 2. 1979;193-249 IARC, Lyon.
48. Li B., Murphy K.L., Laucirica R., Kittrell F., Medina D., Rosen J.M. A transgenic mouse model for mammary carcinogenesis. Oncogene. 16:1998;997-1007.
49. Dragani T.A., Manenti G., Farza H., Della Porta G., Tiollais P., Pourcel C. Transgenic mice containing hepatitis B virus sequences are more susceptible to carcinogen-induced hepatocarcinogenesis. Carcinogenesis. 11:1990;953-956.
50. Kemp C.J., Donehower L.A., Bradley A., Balmain A. Reduction of p53 gene dosages does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell. 74:1993;813-822.
51. Cafaro A., Caputo A., Fracasso C.et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nature Med. 5:1999;643-650.